Jiangsu Tiancheng Biochemical Products

Jiangsu Tiancheng Biochemical Products

Founded in 2006 and anchored by parent Jiangsu Tiancheng Technology Group, the firm built its industrial base manufacturing vitamin E additives, food additives, and basic organic chemicals. The wealth engine traces back to the global livestock feed supply chain — the firm's core products sit upstream from poultry, swine, and aquaculture nutrition across Asia. What distinguishes Tiancheng's investment posture is the deliberate separation of the operating chemical business from a holding company that channels retained earnings into unrelated asset classes. Tiancheng's investment footprint spans three distinct lanes. In financial services, the firm is a major strategic shareholder in Sunshine Insurance Group, one of China's privately held insurers. In real estate, it maintains a portfolio in Hainan Province — a market that has weathered cycles of speculative boom and regulatory intervention. In operating assets, Tiancheng owns a dedicated egg industry production base in Binhai New Area, Haian, alongside its core chemical manufacturing plant and a smart systems R&D center split between Shanghai and Haian. The holding entity — Shenzhen Qianhai Ruilian No. 7 Investment Center, in which Tiancheng holds a 99.99 percent interest — is managed by Huatai Zijin Investment as general partner, suggesting a structured, GP-advised approach to at least one leg of the capital stack. Team size and deployment figures are not publicly disclosed. The firm's geographic concentration remains Jiangsu Province and Hainan, with an export bridge through B K Rekhatex (HK) Ltd., a Hong Kong partner facilitating international chemical distribution. A recent operational push includes the smart systems R&D center in Shanghai — a signal that Tiancheng is layering technology onto its industrial core rather than outsourcing innovation, though no dated public announcement confirms a specific launch timeline. What separates Tiancheng structurally is the use of a Qianhai-domiciled investment vehicle as the aggregator for holding-entity interests — a structure more common among China's cross-border capital allocators than among domestic chemical manufacturers. The separation of industrial operating earnings from the investment holding company, combined with a Silk Road region fund domicile, suggests a governance architecture designed for portfolio expansion that the firm has not yet fully disclosed. No succession plan or family governance framework is publicly documented.